The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. 3]pmol/L, both p<0.001, which persisted after adjustment for a priori confounders. In combined adjusted analyses of cases and controls, sclerostin concentrations were positively related to all bone parameters found to be increased in HBM cases (i.e. L1, total hip and total body DXA BMD, and radial/tibial cortical area, cortical BMD and trabecular density). Whilst these relationships were broadly equivalent in HBM cases and controls, there was some evidence that associations between sclerostin and trabecular phenotypes were stronger in HBM cases, particular for radial trabecular density (interaction p<0.01).
S
clerostin is an endogenous, osteocyte-derived, soluble inhibitor of canonical wnt signaling and a potent inhibitor of osteoblastic bone formation. Despite associations with a range of factors, its role and importance is poorly understood. In contrast protein function and expression analyses have advanced understanding of sclerostin's paracrine effects. However, while circulating sclerostin correlates with bone marrow plasma sclerostin, the extent to which plasma sclerostin 'leakage' reflects underlying bone biology is unclear (1) . Hence, studying plasma sclerostin in a wide range of bone disorders is desirable. Sclerostin concentrations are known to increase with age, immobility, weight loss, the menopause, type II diabetes mellitus, denosumab treatment, and are greater in men than women (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Estrogen replacement, PTH therapy and physical activity, decrease sclerostin in postmenopausal women (1, 3, 12) , while bisphosphonates have variable effects (7, 13, 14) . Oral glucocorticoids decrease sclerostin concentrations acutely, potentially through osteocyte apoptosis (15) .
Sclerostin deficiency, occurring in Sclerosteosis (OMIM 269500) and Van Buchem's disease (OMIM 239100), leads to widespread increased bone mineral density (BMD) and a characteristic skeletal dysplasia including fracture-resistance (16 -18) . Heterozygous carriers have high bone mass (HBM), fracture resistance, but an otherwise normal phenotype (19) , hence current efforts to develop sclerostin antibodies as a novel anabolic osteoporosis treatment. In rodents, in response to mechanical loading (mechanotransduction), osteocytic sclerostin secretion is reduced, alleviating inhibition of osteoblast activity, increasing bone formation and BMD (20, 21) ; raised sclerostin in response to immobility points towards a similar effect in humans (8, 9, 11) . However, the total amount of bone may determine plasma sclerostin concentrations since, in the general population, sclerostin is positively related to total body BMD, particularly in older individuals, and inversely related to bone turnover in men and pre-and postmenopausal women (3, 4, 22) . Recently sclerostin has been positively associated with several microarchitectural parameters including trabecular density, assessed by high resolution pQCT (23) , and cortical vBMD and area, by pQCT (24) .
Elevated sclerostin concentrations have also been reported in a HBM family with a T253I mutation in the wnt pathway regulator low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) (25) . While this may reflect an effect of the mutation on sclerostin metabolism, associations between bone mass, microarchitecture and sclerostin may equally be responsible. Consistent with the latter suggestion, pQCT analysis of a phenotypically similar HBM population revealed differences in a number of microarchitectural parameters, previously related to sclerostin in the general population, including increased trabecular density, cortical vBMD and area (23, 24, 26) . These potential relationships may be complicated further as sclerostin has also been positively associated with fat mass (27) , as has HBM (28); hence sclerostin-bone relationships may be confounded by adiposity.
We planned to improve understanding of the relationships between bone and circulating sclerostin by examining the rare and extreme HBM phenotype. We aimed to determine whether (i) sclerostin concentrations are elevated in HBM, then (ii) if any observed differences are explained by LRP5 HBM mutations, and (iii) any differences reflect an altered relationship between sclerostin and bone parameters in HBM individuals, taking into account established confounding factors.
Materials and Methods

Participant recruitment
The HBM study is a UK based multicenter observational study of adults with unexplained HBM. At 4 of our largest study centers, 406 HBM index cases were identified by screening NHS DXA databases (n ϭ 219,088), excluding scans with significant osteoarthritis and/or other causes of raised BMD (eg, surgical metalwork, Paget's disease, metastases). Full details of DXA database screening and participant recruitment have previously been reported (29) . In brief, HBM was defined as a) both L1 Z-score Նϩ3.2 and total hip Z-score Նϩ1.2 or b) both total hip Z-score Նϩ3.2 and L1 Z-score Նϩ1.2. The L1 lumbar vertebra was used as, in contrast to lower lumbar levels, it was not associated with the presence of lumbar spine osteoarthritis assessed on DXA images (29) . Index cases passed on study invitations to their first-degree relatives and spouse/partner(s). Relatives/ spouses with HBM in turn passed on invitations to their firstdegree relatives/spouses. HBM was defined among spouses as per index cases, and among first-degree relatives as summed L1 Z plus total hip Z-score of Նϩ3.2; reflecting an established family history of HBM. Family-based controls comprised unaffected relatives and spouses. All participants were clinically assessed by one doctor using a standardized structured history and examination questionnaire, after which total body (TB) DXA scans and (nonfasted) phlebotomy were performed. None had a history of parathyroid disease.
Subsequently, current and life-time physical activity (PA) was measured by short (10-minute) postal questionnaire (prepaid reply envelope, sent up to 3 times) which included (i) the short last 7 days self-administered International PA Questionnaire (IPAQ 2002 
Sclerostin and bone turnover markers
Two nonfasted EDTA samples were collected and plasma separated and frozen within 4 hours to -80°C. Sclerostin concentrations were measured using ELISA immunoassay (BI-20442, Biomedica, Vienna, Austria) (detection limit 3.6 pmol/L) (standard range 0 -80 pmol/L). Bone formation (Procollagen type 1 amino-terminal propeptide[PINP], total osteocalcin) and resorption (␤-C-telopeptides of type I collagen[CTX]) markers were also measured. All had interand intra-assay coefficients of variation Ͻ 6.0% across the assay working ranges. Electrochemiluminescence immunoassays (ECLIA) (Roche Diagnostics, Lewes, UK) were used to measure plasma concentrations of PINP, osteocalcin, and CTX (detection limits 4.0, 0.6, 0.01 g/L respectively).
DXA measurements
DXA scans were performed using either GE Lunar Prodigy DXA (software v. 13 (36, 37) . For lumbar spine and hip scans, systematic bias was limited by converting all measures to standardized BMD (sBMD) (38, 39). For TB, systematic differences were limited using cross-calibration equations for all bone and soft tissue regions of interest (37, 40) . Full details have previously been reported, including quality control (QC) checks and grading of TB scans for metallic artifact (28) . Since only 330 (59.5%) of the original multicenter study population (29) had TB DXA scans performed, the principle characteristics of individuals who received a TB DXA scan were compared to those who did not. No differences were observed in weight, height, sex, age, or ethnicity (data not shown).
Peripheral Quantitative Computed Tomography (pQCT) measurements
At are our largest study center, having the necessary equipment, pQCT scanning was performed at the distal and midshaft of the tibia (4 & 66% from distal endplate) and radius (4 & 60%) in nondominant lower and upper limbs respectively, using a Stratec XCT2000L (Stratec Medizintechnik, Pforzheim, Germany); voxel size 0.5 mm, CT speed 30 mm/s, XCT software version 5.50d; details previously described in full (26) . Initial frontal scout view determined a distal endplate reference line. Cortical bone was defined using a threshold Ն 650 mg/cm 3 (optimal for bone geometry (41)). Trabecular bone was identified by elimination of cortical bone and therefore trabecular density was defined as Ͻ 650 mg/cm 3 . Cortical parameters were measured: cortical BMD, total bone area(BA) (ie, total bone cross-section, reflecting periosteal expansion), cortical BA (reflecting combined periosteal and endosteal expansion 
Statistical methods
Descriptive statistics are presented as mean (95% confidence interval (CI)[CI]) for continuous and count (percentages) for categorical data. Analyses comparing two continuous variables are presented as ␤ coefficients and 95%CIs for standardized outcomes. Linear regression was used to analyze continuous variables, using random effects models to allow for the lack of statistical independence due to within-family clustering of environmental factors and shared genotypes. Age, gender, historical/ current PA, height, TB FM, menopausal status and estrogen replacement therapy in women (an established regulator of sclerostin (12)), were considered a priori confounders of associations between HBM status and sclerostin, DXA and bone turnover parameters.
Further potential confounders included: history of malignancy, diabetes mellitus, glucocorticoid (current/previous/never use), antiresorptive medication use (7, (13) (14) (15) . Bone density and microarchitecture analyses were stratified to assess interactions by HBM case/control status. Data were managed using Microsoft Access (data entry checks; error rate Ͻ 0.12%) and analyzed using Stata release 12 statistical software (StataCorp, College Station, TX, USA).
Results
Participant characteristics
In total 202 HBM cases (151 index cases, 49 affected relatives, 2 affected spouses) and 123 family controls (87 unaffected relatives, 36 unaffected spouses) were assessed. HBM cases (age range 26 -90years) were older than family controls (19 -88years), more commonly female, postmenopausal and had used estrogen replacement (Table 1) . Only four HBM cases were not of white European origin.
Plasma sclerostin concentrations
As expected, sclerostin concentrations were strongly associated with age in both HBM cases (unadjusted standardized ␤ per year increase in age 0. [37.2] vs. 58.6 [23.1]pmol/L, P ϭ .042), without evidence of interaction. Sclerostin concentrations were independent of bone turnover markers (overall and in men, women, HBM cases and controls) and TB FM (data not shown).
Unadjusted sclerostin concentrations were significantly higher among HBM cases compared with controls (Table 2 ). These differences were maintained after adjustment for a priori confounders, ie, age, gender, historical/ current PA, height, TB FM, and in women years since menopause and estrogen replacement therapy. Additional adjustment for diabetes mellitus, malignancy, glucocorticoid and antiresorptive use did not influence these findings (Supplementary Table 1) .
To determine the impact of rare cases of HBM caused by anabolic mutations in LRP5, identified by previous Sanger sequencing (43), we firstly assessed sclerostin concentrations in 6 cases of LRP5 HBM, and secondly in the 
Sclerostin and DXA measured BMD
As previously reported (29) , BMD was considerably higher in HBM individuals than controls in unadjusted analyses, and persisted after adjustment for a priori and additional confounders ( Table 2, Supplementary Table 1) . To establish whether sclerostin differences could be explained by variation in BMD, we firstly investigated the relationship between DXA BMD and sclerostin in our combined study population. Before adjustment, strong positive relationships were seen between BMD and sclerostin (␤ represents SD change in sclerostin per SD increase in BMD) measured at L1 (0. (Table 3) , and additional confounders (Supplementary Table 2 ). In further analyses, intended to examine whether BMD-sclerostin relationships differed according to HBM case status, associations were generally stronger between DXA BMD parameters and sclerostin in HBM cases, as judged by ␤ coefficients, especially for L1 BMD; however, despite this no formal HBM case-control interactions were detected (all P Ͼ .05)( Table 3) .
Sclerostin and bone microarchitecture measured by pQCT
The positive relationships observed between DXA measured BMD and sclerostin were next investigated using lower and upper limb pQCT available in 95 HBM No individuals had hypercalcaemia.
cases and 65 controls (4 tibial pQCT images discarded due to movement artifact). When the clinical characteristics of individuals undergoing pQCT assessment were compared to those who did not, no differences were observed in gender, age, weight, height, physical activity, menopausal status or estrogen replacement use (data not shown). Before adjustment, trabecular density was markedly greater at both the tibia and radius, in HBM cases compared with controls, as were cortical density and thickness, albeit to a lesser extent (Table 2) . After adjustment for a priori confounders, trabecular density, cortical density, cortical BA, and SSI, at both the tibia and radius, were all observed to be greater in HBM cases compared with controls; however, bone sizes (total BA) were similar ( Table 2) . Equivalent results were obtained after adjustment for additional confounders (Supplementary Table 1) . Using our regression model adjusted for a priori confounders we assessed the strength of relationships between SD changes in our pQCT measures of bone microarchitecture and sclerostin (standardized). In the study population as a whole, at both the radius and tibia, strong positive relationships were seen between trabecular density, cortical density, cortical BA and sclerostin; a relationship with SSI was only seen at the radius. Sclerostin was independent of bone size (total BA) in both upper and lower limbs (Table 3) . These relationships were unchanged by further adjustment for PINP, plasma CTX and osteocalcin (data not shown), or by further potential confounders (diabetes mellitus, malignancy, glucocorticoid and antiresorptive use)(Supplementary Table 2 ). In stratified analyses, few consistent differences were observed in the relationships between pQCT parameters and sclerostin in HBM cases and controls. The main exception was the association between trabecular density and sclerostin, which was stronger in HBM cases compared to controls at both the radius and tibia, with a formal interaction by case status observed in the upper limb (Table 3, Figure 2 ).
Sensitivity analyses
Relationships between measured (DXA and pQCT) bone parameters and sclerostin were not materially altered 
Discussion
This study is the first to measure circulating sclerostin concentrations in a large population with HBM. We found HBM cases, identified by screening routine NHS DXA databases across the UK, to have substantially increased sclerostin concentrations in comparison to their unaffected family members. Sclerostin concentrations in most of our LRP5 HBM cases, previously identified by capillary sequencing of exons 2, 3 and 4 (43), were higher compared not only to controls, but to the remainder of the HBM population. Our findings are consistent with the one LRP5 HBM family pedigree in which sclerostin has been measured; although the specific mutation differed from ours, average sclerostin concentrations were almost double that of controls, just as we observed (25) . Even after excluding individuals with LRP5 mutations, sclerostin concentrations were significantly higher in our HBM cases than among controls; a difference unchanged by adjustment for factors we confirmed influence sclerostin concentrations, such as age and gender.
The higher sclerostin concentrations among our HBM cases are likely to be, at least partly, explained by the positive relationship between sclerostin and BMD. This relationship, previously reported in population-based studies of lumbar and total hip BMD (4, 13, 22) , was also seen here at L1, total hip and total body BMD among pooled HBM cases and controls. This may reflect an association between sclerostin and total osteocyte number, given that osteocytes are a major source of sclerostin (44, 45) , and BMD reflects the amount of bone tissue and hence osteocyte number. Our microarchitectural analyses support elevated sclerostin concentrations reflecting a greater quantity of bone tissue in HBM cases. As previously reported (26), pQCT analyses revealed HBM cases to have greater cortical and trabecular bone, demonstrated by increased cortical area and trabecular density respectively, both of which showed positive associations with sclerostin in pooled analyses of HBM cases and controls. These findings concur with recent population-based analyses in which sclerostin has been positively related to cortical bone area and trabecular density in older women (24) , and cortical thickness and trabecular density in adult men (23) .
We identified a positive relationship between sclerostin and cortical BMD, as observed in population-based studies (23, 24) ; this may contribute to the increased sclerostin in HBM cases, since cortical BMD is also raised in HBM. Dense cortical bone, with fewer remodeling spaces, may consequently harbor more osteocytes resulting in greater sclerostin production. However, greater cortical BMD may result in greater measured cortical thickness by reducing the impact of partial volume effects which otherwise limit edge detection accuracy in the presence of low cortical BMD. Alternatively, since cortical BMD is inversely related to bone remodeling and turnover, the positive relation between sclerostin and cortical BMD, which we and others have observed, may reflect an inverse association between bone turnover and plasma sclerostin. Such a relationship has previously been suggested in postmenopausal women and older men (3, 22) although potentially not for osteocalcin (12) , although in the present study no association was observed between sclerostin concentrations and bone turnover, despite the validity of our sclerostin assay (46). The clinical utility of sclerostin measurement remains to be determined.
Although sclerostin concentrations were elevated in HBM cases both with and without LRP5 mutations, they were highest in most with LRP5 mutations compared to other HBM cases. This may reflect a more extreme phenotype in LRP5 HBM, with greater amounts of bone tissue (reflected by greater trabecular and cortical bone volumes (26)) and hence osteocyte number, than occurs in non-LRP5 HBM cases. Consistent with this suggestion, sclerostin concentrations observed in our analyses. Interestingly, of the common polymorphisms associated with BMD in large scale genome-wide association studies, gene ontology links several to roles in osteoblastic wnt signaling (49, 52); as discussed above, polymorphisms in these BMD-associated loci occur more frequently in our HBM population.
Importantly, sclerostin is not osteocyte specific; a range of isoforms have been localized in osteoblasts, osteoclasts and chondrocytes (53). In rodent models sclerostin is strongly expressed in ossified ligaments and osteophytes emerging by endochondral ossification (54). HBM has been associated with both ligament ossification, and increased prevalence of joint replacement (potentially due to osteoarthritis) (29, 55) and more recently genetic markers for MEF2C and SOX6, which both have regulatory roles in endochondral ossification (48, 49) .
Limitations
One potential limitation concerns control individuals who comprised relative/spouses rather than being drawn from the general population. These were considered suitable as (i) they had appropriate BMD (Table 1) , (ii) they share common environmental factors with cases which would otherwise be difficult to measure and control for as confounding factors, (iii) their inclusion aids future genetic analyses as trait-associated haplotypes can be readily identified. However, family controls are likely to have been more similar to HBM cases than unrelated population controls; hence clustered analyses were performed to account for the lack of statistical independence due to within-family clustering of environmental factors and shared genotypes. Despite this, our reported differences may still underestimate the true magnitude of the HBM phenotype, than had HBM cases been compared with general population controls. We were able to adjust for differences between cases and controls in gender, postmenopausal status, estrogen replacement, glucocorticoid use and prior history of malignancy which reflect referral indications for clinical DXA services (29) . However, we cannot exclude residual confounding, for example by PTH or renal function; measurements we lacked. Reduced sample size limited analysis of pQCT measurements which were only available in 50%; however, these individuals were representative of the whole study population.
Conclusions
Our case-control study found plasma sclerostin concentrations to be increased in HBM cases compared to family controls. These increases were particularly marked in HBM cases with LRP5 mutations, although cases without LRP5 mutations also had higher sclerostin concentrations compared to controls. Sclerostin was positively related to BMD, measured by DXA, and to trabecular density and cortical area, measured by pQCT, all of which were measures found also to be increased in HBM. Hence, sclerostin concentrations may be increased in HBM in part due to a greater osteocyte number resulting from greater quantities of trabecular and cortical bone tissue. In addition, greater production of sclerostin per unit of bone tissue may contribute to these differences, as suggested by the stronger relationship between sclerostin concentrations and trabecular density in HBM cases compared to controls. Further analyses of relationships between sclerostin and genetic factors predisposing to HBM is justified, to shed new light on the mechanisms regulating sclerostin production.
